BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol 2011; 2(2): 80-93 [PMID: 21603317 DOI: 10.5306/wjco.v2.i2.80]
URL: https://www.wjgnet.com/2218-4333/full/v2/i2/80.htm
(0) (0) (25657) (204)
Number Citing Articles
1
Aishwarya Shinde, Kanan Panchal, Sumeet Katke, Rishi Paliwal, Akash Chaurasiya. Tyrosine kinase inhibitors as next generation oncological therapeutics: Current strategies, limitations and future perspectives. Therapies 2022; 77(4) doi: 10.1016/j.therap.2021.10.010
2
Sanae Baghrous , Ikram Ghicha , Fatiha Bousselham , Roussaint Doussou-Yovo, Hasnaa Bazhar, Youness Kadil , Imane Rahmoune , Houda Filali . Beyond Current Therapies: In Silico Drug Repurposing as a Strategy to Overcome Tyrosine Kinase Inhibitor Resistance in NSCLC. Journal of Drug Delivery and Therapeutics 2025; 15(8) doi: 10.22270/jddt.v15i8.7276
3
Maria Kalyukina, Yuliana Yosaatmadja, Martin J. Middleditch, Adam V. Patterson, Jeff B. Smaill, Christopher J. Squire. TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure. ChemMedChem 2019; 14(4) doi: 10.1002/cmdc.201800719
4
Models of Nanostructures Based on Titanium Dioxide TiO for Transport of Biologically Active Compounds. Nanosistemi, Nanomateriali, Nanotehnologii 2020; 18(4) doi: 10.15407/nnn.18.04.1077
5
Mohammed R. Abdulmonem, Monther F. Mahdi, Ayad M. R. Raauf. Synthesis, characterization, and in silico studies of new benzohydrazide derivatives targeting EGFR kinase. Pharmacia 2026; 73 doi: 10.3897/pharmacia.73.e186971
6
Eman A. Abd El-Meguid, Ahmed M. Naglah, Gaber O. Moustafa, Hanem M. Awad, Ahmed M. El Kerdawy. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Bioorganic & Medicinal Chemistry Letters 2022; 58 doi: 10.1016/j.bmcl.2022.128529
7
Walid E. Elgammal, Hazem Elkady, Mohammed A. Dahab, Hazem A. Mahdy, Mohamed Hagras, Ahmed Nofal, Bshra A. Alsfouk, Eslam B. Elkaeed, Ibrahim H. Eissa, Ahmed M. Metwaly. Design and synthesis of thiadiazoles as anticancer, apoptotic, and VEGFR-2 inhibitors. Future Medicinal Chemistry 2025; 17(8) doi: 10.1080/17568919.2025.2485863
8
Darawan Rinchai, Elena Verzoni, Veronica Huber, Agata Cova, Paola Squarcina, Loris De Cecco, Filippo de Braud, Raffaele Ratta, Matteo Dugo, Luca Lalli, Viviana Vallacchi, Monica Rodolfo, Jessica Roelands, Chiara Castelli, Damien Chaussabel, Giuseppe Procopio, Davide Bedognetti, Licia Rivoltini. Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clinical and Translational Medicine 2021; 11(6) doi: 10.1002/ctm2.434
9
Simone De Leo, Matteo Trevisan, Claudia Moneta, Carla Colombo. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors. Annales d'Endocrinologie 2023; 84(3) doi: 10.1016/j.ando.2023.03.009
10
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017;  doi: 10.1016/B978-0-12-809400-6.00029-9
11
Jijin Wang, Di Huang, Wenjing Yang, Qingxu Song, Yibin Jia, Pengxiang Chen, Yufeng Cheng. The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1030798
12
Venice Wing Tung Ho, Hor Yue Tan, Ning Wang, Yibin Feng. Tyrosine Kinases as Druggable Targets in Cancer. 2019;  doi: 10.5772/intechopen.82513
13
Charles Pottier, Margaux Fresnais, Marie Gilon, Guy Jérusalem, Rémi Longuespée, Nor Eddine Sounni. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers 2020; 12(3) doi: 10.3390/cancers12030731
14
Maša Kenda, Damjan Avsec, Taja Zore, Eva Kogovšek, Urša Pečar Fonović, Janko Kos, Krištof Bozovičar, Tomaž Bratkovič, Nataša Karas Kuželički, Bojana Žegura, Metka Filipič, Marija Sollner Dolenc. Effects of tyrosine kinase inhibitors on androgen, estrogen α, glucocorticoid and thyroid receptors. Toxicology and Applied Pharmacology 2022; 434 doi: 10.1016/j.taap.2021.115818
15
Siva M Gangadhar, Mithilesh Yadav, Nishith S Mandal. Dermatofibrosarcoma Protuberans: A Surgeon's Enigma. Cureus 2023;  doi: 10.7759/cureus.44144
16
Jian Wu, Suresh Kumar, Feng Wang, Hui Wang, Lijia Chen, Patrick Arsenault, Michael Mattern, Joseph Weinstock. Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies. Journal of Medicinal Chemistry 2018; 61(2) doi: 10.1021/acs.jmedchem.7b00498
17
Francesco Sabbatino, Valeria Conti, Luigi Liguori, Giovanna Polcaro, Graziamaria Corbi, Valentina Manzo, Vincenzo Tortora, Chiara Carlomagno, Carmine Vecchione, Amelia Filippelli, Stefano Pepe. Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients. Life 2021; 11(2) doi: 10.3390/life11020105
18
Anh Thu Vu, Lara Akingunsade, Konstantin Hoffer, Cordula Petersen, Christian Stephan Betz, Kai Rothkamm, Thorsten Rieckmann, Lara Bussmann, Malte Kriegs. Src family kinase targeting in head and neck tumor cells using SU6656, PP2 and dasatinib. Head & Neck 2023; 45(1) doi: 10.1002/hed.27216
19
Robert I. Haddad, Martin Schlumberger, Lori J. Wirth, Eric J. Sherman, Manisha H. Shah, Bruce Robinson, Corina E. Dutcus, Angela Teng, Andrew G. Gianoukakis, Steven I. Sherman. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 2017; 56(1) doi: 10.1007/s12020-017-1233-5
20
Shelly Pathania, Olli T. Pentikäinen, Pankaj Kumar Singh. A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2021; 1876(2) doi: 10.1016/j.bbcan.2021.188631
21
Bibian M. E. Tullemans, Magdolna Nagy, Siamack Sabrkhany, Arjan W. Griffioen, Mirjam G. A. oude Egbrink, Maureen Aarts, Johan W. M. Heemskerk, Marijke J. E. Kuijpers. Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients. Frontiers in Cardiovascular Medicine 2018; 5 doi: 10.3389/fcvm.2018.00142
22
E. A. Shatokhina, L. S. Kruglova, A. S. Polonskaia. Management of acneiform rash associated with anti-EGFR monoclonal antibody treatment. Meditsinskiy sovet = Medical Council 2020; (20) doi: 10.21518/2079-701X-2020-20-157-164
23
Wen-Hsing Lin, Su-Ying Wu, Teng-Kuang Yeh, Chiung-Tong Chen, Jen-Shin Song, Hui-Yi Shiao, Ching-Chuan Kuo, Tsu Hsu, Cheng-Tai Lu, Pei-Chen Wang, Tsung-Sheng Wu, Yi-Hui Peng, Hui-You Lin, Ching-Ping Chen, Ya-Ling Weng, Fang-Chun Kung, Mine-Hsine Wu, Yu-Chieh Su, Kuo-Wei Huang, Ling-Hui Chou, Ching-Cheng Hsueh, Kuei-Jung Yen, Po-Chu Kuo, Chen-Lung Huang, Li-Tzong Chen, Chuan Shih, Hui-Jen Tsai, Weir-Torn Jiaang. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia. Journal of Medicinal Chemistry 2019; 62(24) doi: 10.1021/acs.jmedchem.9b01229
24
Fares Hezam Al-Ostoot, Ankith Sherapura, Vikas H. Malojirao, Prabhu Thirusangu, Tahani I. Al-Muhimeed, Shaukath Ara Khanum, B. T. Prabhakar. Modulation of DNA damage response by targeting ATM kinase using newly synthesized di-phenoxy acetamide (DPA) analogs to induce anti-neoplasia. Pharmacological Reports 2021; 73(5) doi: 10.1007/s43440-021-00292-6
25
Sindhu M. Parameshwaraiah, Rashmi Shivakumar, Zhang Xi, Tejaswini P. Siddappa, Akshay Ravish, Arunkumar Mohan, Lisha K. Poonacha, Pradeep M. Uppar, Shreeja Basappa, Dukanya Dukanya, Santhosh L. Gaonkar, Kempaiah Kemparaju, Peter E. Lobie, Vijay Pandey, Basappa Basappa. Development of Novel Indazolyl‐Acyl Hydrazones as Antioxidant and Anticancer Agents that Target VEGFR‐2 in Human Breast Cancer Cells. Chemistry & Biodiversity 2024; 21(3) doi: 10.1002/cbdv.202301950
26
Kelly F. Contino, Jenna Ollodart, Yang Yu, Sun H. Park, Shunsuke Tsuzuki, Kara Rollins, Tyler M. Heethouse, Joshua Chu, Laiton R. Steele, Takahiro Kimura, Jingyun Lee, Cristina M. Furdui, Lance D. Miller, Fang-Chi Hsu, Yusuke Shiozawa. The contribution of stem cell factor and its receptor c-Kit to cancer-induced bone pain. JCI Insight 2026; 11(12) doi: 10.1172/jci.insight.191905
27
Megan L. Troxell, John P. Higgins, Neeraja Kambham. Antineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted Therapies. Advances in Anatomic Pathology 2016; 23(5) doi: 10.1097/PAP.0000000000000122
28
Zachary S. Peacock, Deepak Kademani, Anh D. Le, Janice S. Lee, Robert G. Hale, Larry L. Cunningham. Proceedings From the 2011 American Association of Oral and Maxillofacial Surgeons Research Summit. Journal of Oral and Maxillofacial Surgery 2012; 70(6) doi: 10.1016/j.joms.2012.01.029
29
Aliaksandr Faryna, Elena Kalinichenko. Molecular Docking - Recent Advances. Biomedical Engineering 2023; 15 doi: 10.5772/intechopen.107236
30
Krisyanti Budipramana, Frangky Sangande. Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy. Chemical Biology & Drug Design 2024; 103(5) doi: 10.1111/cbdd.14534
31
Anna M. Ogloblina, Alexandra N. Khristich, Natalia Y. Karpechenko, Svetlana E. Semina, Gennady A. Belitsky, Nina G. Dolinnaya, Marianna G. Yakubovskaya. Multi-targeted effects of G4-aptamers and their antiproliferative activity against cancer cells. Biochimie 2018; 145 doi: 10.1016/j.biochi.2017.11.020
32
Qiao Zhang, Yuxuan Xia, LiYuan Wang, Yang Wang, Yixi Bao, Guo-sheng Zhao. Targeted anti-angiogenesis therapy for advanced osteosarcoma. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1413213
33
Aik-Choon Tan, Simon Vyse, Paul H. Huang. Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discovery Today 2017; 22(1) doi: 10.1016/j.drudis.2016.07.010
34
Katie Bechman, James B Galloway, Kevin L Winthrop. Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections. Current Fungal Infection Reports 2019; 13(4) doi: 10.1007/s12281-019-00350-w
35
Elizabeth Irvine, Casey Williams. Treatment‐, Patient‐, and Disease‐Related Factors and the Emergence of Adverse Events with Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2013; 33(8) doi: 10.1002/phar.1266
36
Mike-Andrew Westhoff, Nicolas Marschall, Klaus-Michael Debatin. Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy. Advances in Experimental Medicine and Biology 2016; 930 doi: 10.1007/978-3-319-39406-0_8
37
Kadri Valter, Boris Zhivotovsky, Vladimir Gogvadze. Cell death-based treatment of neuroblastoma. Cell Death & Disease 2018; 9(2) doi: 10.1038/s41419-017-0060-1
38
Maninder Kaur, Pankaj Kumar Singh, Manjinder Singh, Renu Bahadur, Om Silakari. Molecular dynamics and integrated pharmacophore-based identification of dual $$\hbox {JAK3/PI3K}\delta $$ JAK3/PI3K δ inhibitors. Molecular Diversity 2018; 22(1) doi: 10.1007/s11030-017-9794-z
39
Zhen-Ling Liu, Huan-Huan Chen, Li-Li Zheng, Li-Ping Sun, Lei Shi. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduction and Targeted Therapy 2023; 8(1) doi: 10.1038/s41392-023-01460-1
40
Wagdy M. Eldehna, Eslam Roshdy, Maha-Hamadien Abdulla, Abdelrahman I. Zain-Alabdeen, Moataz A. Shaldam, Noura S. Alhassan, Thamer Bin Traiki, Mohammad M. Al-Sanea, Anwar A. El-Hamaky, Ahmed A. Al-Karmalawy, Ahmed M. El Kerdawy, Manabu Abe, Haytham O. Tawfik. Discovery of 1-phenyl-1,2,3-triazole ureas as dual VEGFR-2/JNK-1 type II kinase inhibitors targeting pancreatic cancer. International Journal of Biological Macromolecules 2025; 308 doi: 10.1016/j.ijbiomac.2025.142372
41
Vikas Pradhan, Salahuddin  , Rajnish Kumar, Avijit Mazumder, Mohammad Mustaqeem Abdullah, Mohammad Shahar Yar, Mohamed Jawed Ahsan, Zabih Ullah. Molecular target interactions of quinoline derivatives as anticancer agents: A review. Chemical Biology & Drug Design 2023; 101(4) doi: 10.1111/cbdd.14196
42
Teresa Vincent, Kunnathur Murugesan Sakthivel, C.M. Reena Josephine, Roopa Prasad, Kathirvelan Chinnadurai, Pavithra Kumar, Mythili Saravanan, Rajan Radha Rasmi. Mechanistic insights into molecular targeted therapy and immunotherapy for lung cancer. Biochemical and Biophysical Research Communications 2025; 776 doi: 10.1016/j.bbrc.2025.152204
43
Özge Sönmez, Nurgül Özgür Yurttaş, İlker İhtiyaroğlu, Halil Mete Çakır, Zeynep Atlı, Tuğrul Elverdi, Ayşe Salihoğlu, Nurhan Seyahi, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Teoman Soysal, Ahmet Emre Eşkazan. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 2024; 24(4) doi: 10.1016/j.clml.2023.12.004
44
Liling Huang, Shiyu Jiang, Yuankai Shi. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). Journal of Hematology & Oncology 2020; 13(1) doi: 10.1186/s13045-020-00977-0
45
Thomas D. McLean, Serena Duchi, Claudia Di Bella. Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review. Targeted Oncology 2022; 17(3) doi: 10.1007/s11523-022-00876-z
46
George Iancu, Dragos Serban, Cristinel Badiu, Ciprian Tanasescu, Mihai Tudosie, Corneliu Tudor, Daniel Costea, Anca Zgura, Raluca Iancu, Danut Vasile. Tyrosine kinase inhibitors in breast cancer (Review). Experimental and Therapeutic Medicine 2021; 23(2) doi: 10.3892/etm.2021.11037
47
K. G. Kulikov, T. V. Koshlan, A. P. Golovitsky. A Paradigm Shift in Experimental Biochemistry: A Priori Estimation of Physical Parameters of Biomolecules. Biophysical Reviews and Letters 2023; 18(01) doi: 10.1142/S1793048023500017
48
Jehan Yahia Al-Humaidi, Sayed Mohamed Riyadh, Basant Farag, Magdi Elsayed Abdelsalam Zaki, Tariq Ziyad Abolibda, Sobhi Mohamed Gomha. Synthesis of Bis-thiazoles Tethered 1,4-Dihydropyridine and Pyridine Linkers via Simple Oxidation and their Molecular Docking as VEGFR -TK Inhibitors. Current Medicinal Chemistry 2025; 32(9) doi: 10.2174/0109298673266044231002071238
49
Jung Hoon Lee, Yanxialei Jiang, Yong Tae Kwon, Min Jae Lee. Pharmacological Modulation of the N-End Rule Pathway and Its Therapeutic Implications. Trends in Pharmacological Sciences 2015; 36(11) doi: 10.1016/j.tips.2015.07.004
50
Prakash Gangadaran, Vidya Sankarapandian, Raksa Arun, Kandasamy Nagarajan ArulJothi, Ramya Lakshmi Rajendran, Ji Min Oh, Athesh Kumaraswamy, Sridharan Gurunagarajan, Byeong-Cheol Ahn. Therapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer. Current Oncology Reports 2026; 28(1) doi: 10.1007/s11912-026-01736-z
51
Yanmin Zhang, Yadong Chen, Danfeng Zhang, Lu Wang, Tao Lu, Yu Jiao. Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines. Journal of Medicinal Chemistry 2018; 61(1) doi: 10.1021/acs.jmedchem.7b01091
52
Tony Tiganis, Nicholas K. Tonks. Mechanisms, functions and therapeutic targeting of protein tyrosine phosphatases. Nature Reviews Molecular Cell Biology 2026; 27(2) doi: 10.1038/s41580-025-00882-9
53
Hassan Izzedine. Toxicités rénales des thérapies ciblées en oncologie. Néphrologie & Thérapeutique 2020; 16(1) doi: 10.1016/j.nephro.2019.06.003
54
Anu R. Melge, K. Manzoor, Shantikumar V. Nair, C. Gopi Mohan. In Silico Drug Design. 2019;  doi: 10.1016/B978-0-12-816125-8.00019-5
55
Praopim Limsakul, Pongsakorn Choochuen, Thawirasm Jungrungrueang, Krit Charupanit. Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative Breast Cancer. International Journal of Molecular Sciences 2024; 25(3) doi: 10.3390/ijms25031405
56
Kenar D. Jhaveri, Rimda Wanchoo, Vipulbhai Sakhiya, Daniel W. Ross, Steven Fishbane. Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. Kidney International Reports 2017; 2(1) doi: 10.1016/j.ekir.2016.09.055
57
Meenu Chopra, Agustin Sgro, Marck Norret, Pilar Blancafort, K. Swaminathan Iyer, Cameron W. Evans. A peptide-functionalised dendronised polymer for selective transfection in human liver cancer cells. New Journal of Chemistry 2021; 45(41) doi: 10.1039/D1NJ01566D
58
Vinayak Venkataraman, John R Bales, Jessie Signorelli, Gabriela S Hobbs. Incidence of bleeding events in patients on concomitant tyrosine kinase inhibitors and selective serotonin reuptake inhibitors. Journal of Oncology Pharmacy Practice 2023; 29(5) doi: 10.1177/10781552221098044
59
Richard J. Honeywell, Ietje Kathmann, Elisa Giovannetti, Carmelo Tibaldi, Egbert F. Smit, Maria N. Rovithi, Henk M.W. Verheul, Godefridus J. Peters. Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. Cancers 2020; 12(11) doi: 10.3390/cancers12113322
60
Vivian Osei Poku, Surtaj Hussain Iram. A critical review on modulators of Multidrug Resistance Protein 1 in cancer cells. PeerJ 2022; 10 doi: 10.7717/peerj.12594
61
Tamer A. Elwaie, Mostafa M. A. Aref, Hamed I. Ali. Advances in the design and discovery of small-molecule tyrosine kinase inhibitors for breast cancer. RSC Advances 2026; 16(34) doi: 10.1039/D6RA03011D
62
Bryan Oronsky, Corey Carter, Anna Scicinska, Arnold Oronsky, Neil Oronsky, Michelle Lybeck, Jan Scicinski. Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy. Oncotarget 2016; 7(8) doi: 10.18632/oncotarget.6984
63
Agnieszka Kotlarz, Małgorzata Przybyszewska, Paweł Swoboda, Jacek Neska, Joanna Miłoszewska, Monika Anna Grygorowicz, Andrzej Kutner, Sergiusz Markowicz. Imatinib inhibits the regrowth of human colon cancer cells after treatment with 5-FU and cooperates with vitamin D analogue PRI-2191 in the downregulation of expression of stemness-related genes in 5-FU refractory cells. The Journal of Steroid Biochemistry and Molecular Biology 2019; 189 doi: 10.1016/j.jsbmb.2019.02.003
64
Ying Xiong, Qinxuan Wang, Yangyi Liu, Jingwen Wei, Xiaolei Chen. Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1023660
65
Shruthi Harish Bindiganavile, Nita Bhat, Andrew G. Lee, Dan S. Gombos, Nagham Al-Zubidi. Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review. Journal of Immunotherapy and Precision Oncology 2021; 4(1) doi: 10.36401/JIPO-20-21
66
Vidya Sagar Jerra, Balajee Ramachandran, Shaik Shareef, Angel Carrillo-Bermejo, Rajamanikandan Sundararaj, Srinivasadesikan Venkatesan. Molecular docking aided machine learning for the identification of potential VEGFR inhibitors against renal cell carcinoma. Medical Oncology 2024; 41(8) doi: 10.1007/s12032-024-02419-0
67
Mojeed Ayoola Ashiru, Sherif Olabisi Ogunyemi, Oluwakemi Rita Temionu, Abosede Christina Ajibare, Nsikak Cicerella Cicero-Mfon, Ogechi Augustina Ihekuna, Monsurat Olatoun Jagun, Latifatu Abdulmumin, Quadri Kolawole Adisa, Yemisi Elizabeth Asibor, Chika Joseph Okorie, Mariam Omowumi Lawal, Musa Oladayo Babalola, Ibrahim Tope Abdulrasaq, Latifat Bukola Salau, Idayat Omotolani Olatunji, Memunat Alake Bankole, Abibat Bisola Daud, Ayodeji Oluwadamilare Adeyemi. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations. Journal of Molecular Modeling 2023; 29(5) doi: 10.1007/s00894-023-05531-6
68
VIDHI DESAI, JYOTSANA THAKKAR, RIMDA WANCHOO, KENAR D. JHAVERI. Onco-Nephrology. 2020;  doi: 10.1016/B978-0-323-54945-5.00026-6
69
Maria Salbini, Alessia Formato, Maria Patrizia Mongiardi, Andrea Levi, Maria Laura Falchetti. Kinase-Targeted Therapies for Glioblastoma. International Journal of Molecular Sciences 2025; 26(8) doi: 10.3390/ijms26083737
70
G. Ganga Reddy, S. Ramakrishna Reddy, Ch. Venkata Ramana Reddy, E. Laxminarayana, B. Srinivasa Reddy. Synthesis, Characterization and Molecular Docking Studies of 5-Chloro-1-(1H-indole-2-yl)-3-methyl-4,5-dihydro-1H-pyrazole-4-carboxylic Acids. Asian Journal of Chemistry 2022; 34(7) doi: 10.14233/ajchem.2022.23610
71
Halyna Kuznietsova, Natalia Dziubenko, Iryna Byelinska, Vasyl Hurmach, Andriy Bychko, Oksana Lynchak, Demyd Milokhov, Olga Khilya, Volodymyr Rybalchenko. Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety. Journal of Drug Targeting 2020; 28(5) doi: 10.1080/1061186X.2019.1703189
72
Marília I. Figueira, Henrique J. Cardoso, Sara Correia, Cláudio J. Maia, Sílvia Socorro. The stem cell factor (SCF)/c-KIT system in carcinogenesis of reproductive tissues: What does the hormonal regulation tell us?. Cancer Letters 2017; 405 doi: 10.1016/j.canlet.2017.07.017
73
Burcu Cakar, Erdem Göker. Breast Disease. 2016;  doi: 10.1007/978-3-319-26012-9_36
74
Attila Varga, Pál Gyulavári, Zoltán Greff, Krisztina Futosi, Tamás Németh, Laura Simon-Szabó, Krisztina Kerekes, Csaba Szántai-Kis, Diána Brauswetter, Márton Kokas, Gábor Borbély, Anna Erdei, Attila Mócsai, György Kéri, Tibor Vántus, Ramani Ramchandran. Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro. PLOS ONE 2015; 10(4) doi: 10.1371/journal.pone.0124234
75
Anne Close. Antiangiogenesis and Vascular Disrupting Agents in Cancer: Circumventing Resistance and Augmenting Their Therapeutic Utility. Future Medicinal Chemistry 2016; 8(4) doi: 10.4155/fmc.16.6
76
Wagdy M. Eldehna, Sara T. Al-Rashood, Tarfah Al-Warhi, Razan O. Eskandrani, Amal Alharbi, Ahmed M. El Kerdawy. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry 2021; 36(1) doi: 10.1080/14756366.2020.1862101
77
Sangeetha Reddy, Michael Raffin, Virginia Kaklamani. Targeting Angiogenesis in Metastatic Breast Cancer. The Oncologist 2012; 17(8) doi: 10.1634/theoncologist.2012-0043
78
Suchandra Roy Acharyya, Plaboni Sen, Thirukumaran Kandasamy, Siddhartha Sankar Ghosh. Dual therapeutic approach to modulate Glycogen Synthase kinase −3 beta (GSK-3Β) and inhibitor of nuclear factor kappa kinase-beta (IKK-β) receptors by in silico designing of inhibitors. Journal of Molecular Graphics and Modelling 2022; 115 doi: 10.1016/j.jmgm.2022.108225
79
I. Duran, J. Lambea, P. Maroto, J. L. González-Larriba, Luis Flores, S. Granados-Principal, M. Graupera, B. Sáez, A. Vivancos, O. Casanovas. Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. Targeted Oncology 2017; 12(1) doi: 10.1007/s11523-016-0463-4
80
Ching-Liang Chu, Yi-Pang Lee, Cheng-Yoong Pang, Huei-Ru Lin, Chang-Shan Chen, Ren-In You. Tyrosine kinase inhibitors modulate dendritic cell activity via confining c-Kit signaling and tryptophan metabolism. International Immunopharmacology 2020; 82 doi: 10.1016/j.intimp.2020.106357
81
Amal A.M. Eissa, Kholoud F.M. Aljamal, Hany S. Ibrahim, Heba Abdelrasheed Allam. Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity. Bioorganic Chemistry 2021; 116 doi: 10.1016/j.bioorg.2021.105318
82
Heba T. Abdel‐Mohsen, Eman A. Abd El‐Meguid, Ahmed M. El Kerdawy, Abeer E. E. Mahmoud, Mamdouh M. Ali. Design, synthesis, and molecular docking of novel 2‐arylbenzothiazole multiangiokinase inhibitors targeting breast cancer. Archiv der Pharmazie 2020; 353(4) doi: 10.1002/ardp.201900340
83
Jaymin J. Kathiriya, Ravi Ramesh Pathak, Alexandr Bezginov, Bin Xue, Vladimir N. Uversky, Elisabeth R.M. Tillier, Vrushank Davé. Structural pliability adjacent to the kinase domain highlights contribution of FAK1 IDRs to cytoskeletal remodeling. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2017; 1865(1) doi: 10.1016/j.bbapap.2016.10.002
84
Paulina Stachyra‑Strawa, Marzanna Ciesielka, Michał Janiszewski, Ludmiła Grzybowska‑Szatkowska. The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review). Oncology Reports 2021; 46(2) doi: 10.3892/or.2021.8109
85
Jean-Jacques Helesbeux, Laura Carro, Florence O. McCarthy, Vânia M. Moreira, Francesca Giuntini, Niamh O’Boyle, Susan E. Matthews, Gülşah Bayraktar, Samuel Bertrand, Christophe Rochais, Pascal Marchand. 29th Annual GP2A Medicinal Chemistry Conference. Pharmaceuticals 2021; 14(12) doi: 10.3390/ph14121278
86
Chayanon Ngambenjawong, Heather H. Gustafson, Suzie H. Pun. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Advanced Drug Delivery Reviews 2017; 114 doi: 10.1016/j.addr.2017.04.010
87
H. M. Kuznietsova. Effect of dihydropyrrol and maleimide derivatives on the state of the liver and colon in normal rats and those with colorectal carcinogenesis induced by dimethylhydrazine. The Ukrainian Biochemical Journal 2013; 85(3) doi: 10.15407/ubj85.03.074
88
Nurmaya Effendi, Kenji Mishiro, Takeshi Takarada, Daisuke Yamada, Ryuichi Nishii, Kazuhiro Shiba, Seigo Kinuya, Akira Odani, Kazuma Ogawa. Design, synthesis, and biological evaluation of radioiodinated benzo[d]imidazole-quinoline derivatives for platelet-derived growth factor receptor β (PDGFRβ) imaging. Bioorganic & Medicinal Chemistry 2019; 27(2) doi: 10.1016/j.bmc.2018.12.016
89
Godefridus J. Peters. Nucleo(s)tide metabolism as basis for drug development; the Anne Simmonds award lecture. Nucleosides, Nucleotides & Nucleic Acids 2024; 43(8) doi: 10.1080/15257770.2024.2383681
90
Yongtao Zhang, Chao Zhou, Qiong Xie, Linying Xia, Qingping Li, Lu Liu, Hongming Lin, Xiaochun Xiong, Jiayi Zhao, Wenqing Liang. Nanotechnology revolutionizing osteosarcoma treatment: Advances in targeted kinase inhibitors. Nanotechnology Reviews 2025; 14(1) doi: 10.1515/ntrev-2025-0147
91
T. V. Koshlan, K. G. Kulikov. Analysis to determine the effect of mutations on binding to small chemical molecules. Journal of Bioinformatics and Computational Biology 2022; 20(02) doi: 10.1142/S0219720022400030
92
Eri Yamabayashi, Yoshinari Obata, Junji Kozawa, Hitoshi Nishizawa, Iichiro Shimomura. Mild Primary Adrenal Insufficiency During Treatment With Lenvatinib and Pembrolizumab: A Report of 3 Patients. JCEM Case Reports 2025; 3(8) doi: 10.1210/jcemcr/luaf123
93
Kalyani Asgaonkar, Sushruti Tanksali, Kshitija Abhang, Ashwini Sagar. Development of optimized pyrimido-thiazole scaffold derivatives as anticancer and multitargeting tyrosine kinase inhibitors using computational studies. Journal of the Indian Chemical Society 2023; 100(1) doi: 10.1016/j.jics.2022.100803
94
Pedro A. Ruiz-Castro, Duncan Shaw, Gabor Jarai. Discoidin Domain Receptors in Health and Disease. 2016;  doi: 10.1007/978-1-4939-6383-6_12
95
Saveria Pastore, Daniela Lulli, Giampiero Girolomoni. Replica to K. Takeda et al. Commentary to Pastore et al. (2014): Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Archives of Toxicology 2014; 88(12) doi: 10.1007/s00204-014-1399-z
96
Shlomit Tamir, Shlomo Gavrielli, Chen Abitbol, Noam Tau, Ahuva Grubstein, Victoria Neiman, Lilach Yosef, Eli Atar, Alona Zer. Association between multitarget tyrosine kinase inhibitors and changes in CT appearance of submucosal fat in the gastrointestinal tract. Tumori Journal 2021; 107(5) doi: 10.1177/0300891621995893
97
Heba T. Abdel-Mohsen, Marwa A. Ibrahim, Amira M. Nageeb, Ahmed M. El Kerdawy. Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors. BMC Chemistry 2024; 18(1) doi: 10.1186/s13065-024-01135-0
98
Yara A. Zaky, Mai W. Rashad, Marwa A. Zaater, Ahmed M. El Kerdawy. Discovery of dual rho-associated protein kinase 1 (ROCK1)/apoptosis signal–regulating kinase 1 (ASK1) inhibitors as a novel approach for non-alcoholic steatohepatitis (NASH) treatment. BMC Chemistry 2024; 18(1) doi: 10.1186/s13065-023-01081-3
99
Marcin Nosal. Progressive Destructive Hypothyroidism Associated with Sunitinib Therapy: A Three-Year Case Analysis. Journal of Clinical Medicine 2026; 15(2) doi: 10.3390/jcm15020788
100
Aleksandra Sochacka-Ćwikła, Marcin Mączyński, Andrzej Regiec. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 2022; 27(7) doi: 10.3390/molecules27072259
101
Areej Abuhammad, Mutasem Taha. Innovative Computer-Aided Methods for the Discovery of New Kinase Ligands. Future Medicinal Chemistry 2016; 8(5) doi: 10.4155/fmc-2015-0003
102
Sanja Aveic, Gian Paolo Tonini. Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?. Cancer Cell International 2016; 16(1) doi: 10.1186/s12935-016-0341-2
103
Rohit Patel, Johnna Francis Varghese. Receptor Tyrosine Kinases in Cancer. Cancer Drug Discovery and Development 2025;  doi: 10.1007/978-3-031-93894-8_9
104
Mingyue Luo, Lu Sun, Rongping Dai, Youxin Chen, Chan Wu. Central retinal vein occlusion in patients with metastatic solid tumors on tyrosine kinase inhibitors: a report of case series and literature review. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1362108
105
Cristina Olgasi, Patrizia Dentelli, Arturo Rosso, Alessandra Iavello, Gabriele Togliatto, Valentina Toto, Marcella Liberatore, Giuseppina Barutello, Piero Musiani, Federica Cavallo, Maria Felice Brizzi. DNA vaccination against membrane-bound Kit ligand: A new approach to inhibiting tumour growth and angiogenesis. European Journal of Cancer 2014; 50(1) doi: 10.1016/j.ejca.2013.09.016
106
Nastaran Masoudi-Khoram, Sara Cheraghi, Mahboobeh Nazari, Mohammad E. Khamseh. Targeting endothelial growth factor receptor in thyroid cancer: current concepts and future directions. Medical Oncology 2025; 42(7) doi: 10.1007/s12032-025-02788-0
107
Sara Sultan, Ruba A. Zenati, Hanan S. Anbar, Mohammed I. El‐Gamal, Mohammad H. Semreen. Recent Advances of Quinoline‐Based Small Molecules as Kinase Inhibitors (2020–2024). ChemMedChem 2025; 20(14) doi: 10.1002/cmdc.202500279
108
Xiaoxiao Sun, Qiaoling Song, Li He, Lei Yan, Jingli Liu, Qing Zhang, Qiang Yu. Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment. Molecular Cancer Therapeutics 2016; 15(10) doi: 10.1158/1535-7163.MCT-15-0735
109
Sareshma Sudhesh Dev, Syafiq Asnawi Zainal Abidin, Reyhaneh Farghadani, Iekhsan Othman, Rakesh Naidu. Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.772510
110
Bashdar Mahmud Hussen, Khozga Hazhar Abdullah, Snur Rasool Abdullah, Nasik Mahmood Majeed, Sayran Mohamadtahr, Mohammed Fatih Rasul, Peixin Dong, Mohammad Taheri, Majid Samsami. New insights of miRNA molecular mechanisms in breast cancer brain metastasis and therapeutic targets. Non-coding RNA Research 2023; 8(4) doi: 10.1016/j.ncrna.2023.09.003
111
Priyanka Gupta, Keehn Strange, Rahul Telange, Ailan Guo, Heather Hatch, Amin Sobh, Jonathan Elie, Angela M. Carter, John Totenhagen, Chunfeng Tan, Yogesh A. Sonawane, Jiri Neuzil, Amarnath Natarajan, Ashley J. Ovens, Jonathan S. Oakhill, Thorsten Wiederhold, Karel Pacak, Hans K. Ghayee, Laurent Meijer, Sushanth Reddy, James Bibb. Genetic Impairment of Succinate Metabolism Disrupts Bioenergetic Sensing in Adrenal Neuroendocrine Cancer. SSRN Electronic Journal 2022;  doi: 10.2139/ssrn.4018612
112
Samu John, Dhanya Kalathil, Chithra J.S.. Phytochemicals and Hallmarks of Cancer. 2026;  doi: 10.1016/B978-0-443-34084-0.00005-4
113
Mustafa A. Al-Qadhi, Heba Abdelrasheed Allam, Samar H. Fahim, Tawfeek A.A. Yahya, Fatma A.F. Ragab. Design and synthesis of certain 7-Aryl-2-Methyl-3-Substituted Pyrazolo{1,5-a}Pyrimidines as multikinase inhibitors. European Journal of Medicinal Chemistry 2023; 262 doi: 10.1016/j.ejmech.2023.115918
114
Aiten M. Soliman, Mostafa M. Ghorab. Exploration of N-alkyl-2-[(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydroquinazolin-2-yl)thio]acetamide derivatives as anticancer and radiosensitizing agents. Bioorganic Chemistry 2019; 88 doi: 10.1016/j.bioorg.2019.102956
115
Eman M.E. Dokla, Amal Kamal Abdel-Aziz, Sandra N. Milik, Amr H. Mahmoud, Mona Kamal Saadeldin, Martin J. McPhillie, Saverio Minucci, Khaled A.M. Abouzid. Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer. Bioorganic Chemistry 2021; 117 doi: 10.1016/j.bioorg.2021.105451
116
Sanjay K. Srikakulam, Tomas Bastys, Olga V. Kalinina. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance. Proteins: Structure, Function, and Bioinformatics 2020; 88(11) doi: 10.1002/prot.25963
117
Samy Mohamady, Mahmoud Galal, Wagdy M. Eldehna, David C. Gutierrez, Hany S. Ibrahim, Mohey M. Elmazar, Hamed I. Ali. Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors. ACS Omega 2020; 5(30) doi: 10.1021/acsomega.0c02038
118
Adriana Zámečníkova. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer. Expert Opinion on Drug Discovery 2014; 9(1) doi: 10.1517/17460441.2014.865012
119
Nurmaya Effendi, Kenji Mishiro, Takeshi Takarada, Akira Makino, Daisuke Yamada, Yoji Kitamura, Kazuhiro Shiba, Yasushi Kiyono, Akira Odani, Kazuma Ogawa. Radiobrominated benzimidazole-quinoline derivatives as Platelet-derived growth factor receptor beta (PDGFRβ) imaging probes. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-28529-0
120
Wagdy M. Eldehna, Ahmed M. El Kerdawy, Ghada H. Al-Ansary, Sara T. Al-Rashood, Mamdouh M. Ali, Abeer E. Mahmoud. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. European Journal of Medicinal Chemistry 2019; 163 doi: 10.1016/j.ejmech.2018.11.061
121
Kyaw Zwar Myint, Brinda Balasubramanian, Simran Venkatraman, Suchada Phimsen, Supisara Sripramote, Jeranan Jantra, Chaiwat Choeiphuk, Somkit Mingphruedhi, Paramin Muangkaew, Narongsak Rungsakulkij, Pongsatorn Tangtawee, Wikran Suragul, Watoo Vassanasiri Farquharson, Kanokpan Wongprasert, Somchai Chutipongtanate, Pimtip Sanvarinda, Marisa Ponpuak, Naravat Poungvarin, Tavan Janvilisri, Tuangporn Suthiphongchai, Kiren Yacqub-Usman, Anna M. Grabowska, David O. Bates, Rutaiwan Tohtong. Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. Pharmaceuticals 2024; 17(2) doi: 10.3390/ph17020197
122
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017;  doi: 10.1016/B978-0-12-809400-6.00007-X
123
Josep Tabernero, Rocio Garcia-Carbonero, James Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Irina Davidenko, Ramon Salazar, Liubov Vladimirova, Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, Irina Bulavina, Vanessa Potter, Yu-Lin Chang, Nathalie A. Lokker, Peter J. O'Dwyer. Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial. Clinical Cancer Research 2013; 19(9) doi: 10.1158/1078-0432.CCR-13-0107
124
Wenjing Xu, Chunping Ye, Xin Qing, Shengli Liu, Xinyi Lv, Wenjun Wang, Xiaochen Dong, Yewei Zhang. Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. Materials Today Bio 2022; 16 doi: 10.1016/j.mtbio.2022.100358
125
Valentina Gandin, Alessandro Ferrarese, Martina Dalla Via, Cristina Marzano, Adriana Chilin, Giovanni Marzaro. Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Scientific Reports 2015; 5(1) doi: 10.1038/srep16750
126
Gabor Valcz, Ferenc Sipos, Zsolt Tulassay, Bela Molnar, Yukako Yagi. Republished: Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology. Postgraduate Medical Journal 2015; 91(1075) doi: 10.1136/postgradmedj-2014-202561rep
127
Rania Kheder El-Fekih, Clément Deltombe, Hassan Izzedine. Microangiopathie thrombotique et cancer. Néphrologie & Thérapeutique 2017; 13(6) doi: 10.1016/j.nephro.2017.01.023
128
Sheetal Chauhan, Seema Sen, Khushboo Irshad, Seema Kashyap, Neelam Pushker, Rachna Meel, Mehar Chand Sharma. Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target. Human Cell 2023; 37(1) doi: 10.1007/s13577-023-00993-5
129
Mohamed Abdel-Megid, Mostafa E. Salem, Aliaa H. El-boghdady, Ahmed A. El-Rashedy, Mohammed T. Abdel-Aal, Amr Nassrallah, Asmaa Aboelnaga, Mohamed G. Abouelenein. Novel Pyrano[2,3-c]pyrazole derivatives: Synthesis, spectroscopic characterization, and In Silico evaluation of interactions with VEGFR-1 and aromatase. Journal of Molecular Structure 2025; 1347 doi: 10.1016/j.molstruc.2025.143107
130
Mohammad Amin Habibi, Farhang Rashidi, Bardia Hajikarimloo, Shaghayegh Karami, Sahar Fathi Tavani, Amirhossein Zare, Mohammad Sina Mirjani, Ali Allahdadi, Kimia Didehvar, Ibrahim Mohammadzadeh, Mohammad Amin Kaviari. The safety and efficacy of VEGFR tyrosine kinase inhibitors for patients with gliomas: a systematic review, meta-analysis, and a specific analysis on glioblastoma. Neurosurgical Review 2025; 48(1) doi: 10.1007/s10143-025-03536-8
131
Josep Esteve Romero, Jaume Albiol Chiva, Juan Peris-Vicente, Enrique Ochoa-Aranda. Development and Validation of A Micellar Liquid Chromatographic Method to Determine Three Antitumorals in Plasma. Bioanalysis 2017; 9(10) doi: 10.4155/bio-2017-0028
132
Amirrtha Srikanthan, Josee-Lyne Ethier, Alberto Ocana, Bostjan Seruga, Monika K. Krzyzanowska, Eitan Amir, Jung Weon Lee. Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study. PLOS ONE 2015; 10(3) doi: 10.1371/journal.pone.0122735
133
Jianbiao Zhou, Wee-Joo Chng. Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies. World Journal of Clinical Oncology 2018; 9(5): 90-97 doi: 10.5306/wjco.v9.i5.90
134
Е.А. Шатохина, А.Г. Туркина, Л.С. Круглова, С.В. Журавлев. ТЕРАПИЯ ДЕРМАТОЛОГИЧЕСКИХ НЕЖЕЛАТЕЛЬНЫХ ЯВЛЕНИЙ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ BCR-ABL . Restorative Dermatology and Venereology and Cosmetology 2026; (1) doi: 10.46393/3034722X_2026_1_6-14
135
Gabor Valcz, Ferenc Sipos, Zsolt Tulassay, Bela Molnar, Yukako Yagi. Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology. Journal of Clinical Pathology 2014; 67(12) doi: 10.1136/jclinpath-2014-202561
136
Mohammed S. Abdel-Maksoud, Hebatollah E. Eitah, Rasha M. Hassan, Walaa Hamada Abd-Allah. Design and synthesis of novel pyrimidine-pyrazole hybrids with dual anticancer and anti-inflammatory effects targeting BRAFV600E and JNK. Molecular Diversity 2025; 29(6) doi: 10.1007/s11030-025-11121-w
137
Haoyue Guo, Binglei Li, Li Diao, Hao Wang, Peixin Chen, Minlin Jiang, Lishu Zhao, Yayi He, Caicun Zhou. An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC). OncoImmunology 2021; 10(1) doi: 10.1080/2162402X.2021.1947665
138
Fahua Deng, Weijie Ma, Sixi Wei. Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances. Cancers 2026; 18(2) doi: 10.3390/cancers18020207
139
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017;  doi: 10.1016/B978-0-12-809400-6.00003-2
140
Nadia Panera, Annalisa Crudele, Ilaria Romito, Daniela Gnani, Anna Alisi. Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2017; 18(1) doi: 10.3390/ijms18010099
141
Mohamed Mokhtar, Khadijah S. Alghamdi, Nesreen S. Ahmed, Dina Bakhotmah, Tamer S. Saleh. Design and green synthesis of novel quinolinone derivatives of potential anti-breast cancer activity against MCF-7 cell line targeting multi-receptor tyrosine kinases. Journal of Enzyme Inhibition and Medicinal Chemistry 2021; 36(1) doi: 10.1080/14756366.2021.1944126
142
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan. From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy. British Journal of Clinical Pharmacology 2026;  doi: 10.1002/bcp.70565
143
Halyna M. Kuznietsova, Vasyl V. Hurmach, Andriy V. Bychko, Olena I. Tykhoniuk, Demyd S. Milokhov, Olga V. Khilya, Yulian M. Volovenko, Volodymyr K. Rybalchenko. Synthesis and biological activity of 4-amino-3-chloro-1H-pyrrole-2,5-diones. In Silico Pharmacology 2019; 7(1) doi: 10.1007/s40203-019-0051-2
144
Heba Abdelrasheed Allam, Enayat E. Aly, Ahmed K.B.A.W. Farouk, Ahmed M. El Kerdawy, Essam Rashwan, Safinaz E.S. Abbass. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents. Bioorganic Chemistry 2020; 98 doi: 10.1016/j.bioorg.2020.103726
145
Michaela Kuhlen, Jan-Henning Klusmann, Jessica I. Hoell. Molecular Approaches to Treating Pediatric Leukemias. Frontiers in Pediatrics 2019; 7 doi: 10.3389/fped.2019.00368
146
Pascal Dao, Rafika Jarray, Nikaia Smith, Yves Lepelletier, Johanne Le Coq, Daniel Lietha, Réda Hadj-Slimane, Jean-Philippe Herbeuval, Christiane Garbay, Françoise Raynaud, Huixiong Chen. Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities. Cancer Letters 2014; 348(1-2) doi: 10.1016/j.canlet.2014.03.007
147
Andoni Garitano-Trojaola, Ana Sancho, Ralph Götz, Patrick Eiring, Susanne Walz, Hardikkumar Jetani, Jesus Gil-Pulido, Matteo Claudio Da Via, Eva Teufel, Nadine Rhodes, Larissa Haertle, Estibaliz Arellano-Viera, Raoul Tibes, Andreas Rosenwald, Leo Rasche, Michael Hudecek, Markus Sauer, Jürgen Groll, Hermann Einsele, Sabrina Kraus, Martin K. Kortüm. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. Communications Biology 2021; 4(1) doi: 10.1038/s42003-021-02215-w
148
Miaomiao Tang, Zhanxuan E. Wu, Fei Li. Integrating network pharmacology and drug side-effect data to explore mechanism of liver injury-induced by tyrosine kinase inhibitors. Computers in Biology and Medicine 2024; 170 doi: 10.1016/j.compbiomed.2024.108040
149
M J Cross, B R Berridge, P J M Clements, L Cove‐Smith, T L Force, P Hoffmann, M Holbrook, A R Lyon, H R Mellor, A A Norris, M Pirmohamed, J D Tugwood, J E Sidaway, B K Park. Physiological, pharmacological and toxicological considerations of drug‐induced structural cardiac injury. British Journal of Pharmacology 2015; 172(4) doi: 10.1111/bph.12979
150
Vikash Pandey, Marc Sultan, Karl Kashofer, Meryem Ralser, Vyacheslav Amstislavskiy, Julia Starmann, Ingrid Osprian, Christina Grimm, Hendrik Hache, Marie-Laure Yaspo, Holger Sültmann, Michael Trauner, Helmut Denk, Kurt Zatloukal, Hans Lehrach, Christoph Wierling, Manlio Vinciguerra. Comparative Analysis and Modeling of the Severity of Steatohepatitis in DDC-Treated Mouse Strains. PLoS ONE 2014; 9(10) doi: 10.1371/journal.pone.0111006
151
Aisha Al Anaz, Ravi Teja Chitturi Suryaprakash, Kate Shearston, Omar Kujan. Molecular Targets and Cancer Therapeutics (Part 1). 2023;  doi: 10.2174/9789815080384123010008
152
Daniel J. De Klerk, Richard J. Honeywell, Gerrit Jansen, Godefridus J. Peters. Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. Cancers 2018; 10(12) doi: 10.3390/cancers10120503
153
Dong-Myung Kim, Hanna Kim, Ji-Hyun Yeon, Ju-Hee Lee, Han-Oh Park. Identification of a Mitochondrial DNA Polymerase Affecting Cardiotoxicity of Sunitinib Using a Genome-Wide Screening onS. pombeDeletion Library. Toxicological Sciences 2016; 149(1) doi: 10.1093/toxsci/kfv210
154
Carmen Dominguez-Brauer, Kelsie L. Thu, Jacqueline M. Mason, Heiko Blaser, Mark R. Bray, Tak W. Mak. Targeting Mitosis in Cancer: Emerging Strategies. Molecular Cell 2015; 60(4) doi: 10.1016/j.molcel.2015.11.006
155
Shih-Chung Yen, Yi-Wen Wu, Cheng-Chiao Huang, Min-Wu Chao, Huang-Ju Tu, Liang-Chieh Chen, Tony Eight Lin, Tzu-Ying Sung, Hui-Ju Tseng, Jung-Chun Chu, Wei-Jan Huang, Chia-Ron Yang, Wei-Chun HuangFu, Shiow-Lin Pan, Kai-Cheng Hsu. O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia. Phytomedicine 2022; 100 doi: 10.1016/j.phymed.2022.154061
156
Prakamya Gupta, Ashutosh Rai, Kanchan Kumar Mukherjee, Naresh Sachdeva, Bishan Das Radotra, Raj Pal Singh Punia, Rakesh Kumar Vashista, Debasish Hota, Anand Srinivasan, Sivashanmugam Dhandapani, Sunil Kumar Gupta, Anil Bhansali, Pinaki Dutta. Imatinib Inhibits GH Secretion From Somatotropinomas. Frontiers in Endocrinology 2018; 9 doi: 10.3389/fendo.2018.00453
157
Wei Zhao, Xiao‐Di Zheng, Paula Yun‐Zhi Tang, Hong‐Mei Li, Xue Liu, Jian‐Jiang Zhong, Ya‐Jie Tang. Advances of antitumor drug discovery in traditional Chinese medicine and natural active products by using multi‐active components combination. Medicinal Research Reviews 2023; 43(5) doi: 10.1002/med.21963
158
Raja Nur Firzanah Syaza Raja Sharin, Jesmine Khan, Mohamad Johari Ibahim, Mudiana Muhamad, Joanne Bowen, Wan Nor I’zzah Wan Mohamad Zain, Supat Chupradit. Role of ErbB1 in the Underlying Mechanism of Lapatinib‐Induced Diarrhoea: A Review. BioMed Research International 2022; 2022(1) doi: 10.1155/2022/4165808
159
Aarthi Jayanthan, Yibing Ruan, Tony H. Truong, Aru Narendran, Claude Prigent. Aurora Kinases as Druggable Targets in Pediatric Leukemia: Heterogeneity in Target Modulation Activities and Cytotoxicity by Diverse Novel Therapeutic Agents. PLoS ONE 2014; 9(7) doi: 10.1371/journal.pone.0102741
160
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017;  doi: 10.1016/B978-0-12-809400-6.00009-3
161
Sunitha Shyam Sunder, Umesh C. Sharma, Saraswati Pokharel. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduction and Targeted Therapy 2023; 8(1) doi: 10.1038/s41392-023-01469-6
162
Sizhe Zhang, Xuecong Tian, Chen Chen, Ying Su, Wanhua Huang, Xiaoyi Lv, Cheng Chen, Hongyi Li. AIGO-DTI: Predicting Drug–Target Interactions Based on Improved Drug Properties Combined with Adaptive Iterative Algorithms. Journal of Chemical Information and Modeling 2024; 64(10) doi: 10.1021/acs.jcim.4c00584
163
Huda K. Mahmoud, Thoraya A. Farghaly, Hanan G. Abdulwahab, Nadia T. Al-Qurashi, Mohamed R. Shaaban. Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity. European Journal of Medicinal Chemistry 2020; 208 doi: 10.1016/j.ejmech.2020.112752
164
Frangky Sangande, Elin Julianti, Daryono Hadi Tjahjono. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2. International Journal of Molecular Sciences 2020; 21(20) doi: 10.3390/ijms21207779
165
Simona Stankeviciute, Ariel Tsai, Noha Rayad, Matthias Kruse. The pH factor: unraveling drug-drug interactions in protein kinase inhibitors through the regulatory lens. Translational and Clinical Pharmacology 2026; 34(1) doi: 10.12793/tcp.2026.34.e6
166
Sebastian Kallus, Bernhard Englinger, Julia Senkiv, Anna Laemmerer, Petra Heffeter, Walter Berger, Christian R. Kowol, Bernhard K. Keppler. Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. Nanomedicine: Nanotechnology, Biology and Medicine 2018; 14(8) doi: 10.1016/j.nano.2018.08.001
167
Behzad Jafari, Maryam Hamzeh-Mivehroud, Michael B. Morris, Siavoush Dastmalchi. Exploitation of phage display for the development of anti-cancer agents targeting fibroblast growth factor signaling pathways: New strategies to tackle an old challenge. Cytokine & Growth Factor Reviews 2019; 46 doi: 10.1016/j.cytogfr.2019.03.002
168
Bradley D. Menz, Jacinta L. Johnson, Davina F. Gillard, William Chong, Michael B. Ward. The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events. Journal of Pharmacy Practice 2021; 34(3) doi: 10.1177/0897190019872937
169
Tasuku Matsuoka, Masakazu Yashiro. Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges. World Journal of Gastrointestinal Oncology 2021; 13(5): 366-390 doi: 10.4251/wjgo.v13.i5.366
170
Suman Birbal Chauhan, Uttam A. More, Malleshappa N. Noolvi. Benzimidazole derivatives as kinase inhibitors: Synthetic strategies, and therapeutic prospects in cancer. Letters in Drug Design & Discovery 2026; 23(2) doi: 10.1016/j.lddd.2026.100372
171
Myron Wilde, Danielle Arzur, Blandine Baratte, Dorian Lefebvre, Thomas Robert, Thierry Roisnel, Catherine Le Jossic-Corcos, Stéphane Bach, Laurent Corcos, William Erb. Regorafenib analogues and their ferrocenic counterparts: synthesis and biological evaluation. New Journal of Chemistry 2020; 44(45) doi: 10.1039/D0NJ05334A
172
Thomas Drabison, Mike Boeckman, Yan Yang, Kevin M. Huang, Peter de Bruijn, Mahesh R. Nepal, Josie A. Silvaroli, Anika T. Chowdhury, Eric D. Eisenmann, Xiaolin Cheng, Navjotsingh Pabla, Ron H.J. Mathijssen, Sharyn D. Baker, Shuiying Hu, Alex Sparreboom, Zahra Talebi. Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen. Cancer Research Communications 2024; 4(9) doi: 10.1158/2767-9764.CRC-24-0332
173
Koki Nakamura, Atsuko Miyoshi, Daigo Nakazawa, Yuki Hamakawa, Hidenori Amaike, Ken Nagahata, Kuniyuki Aso, Hiroki Takahashi, Masatoshi Kanda. Nintedanib and neutrophil extracellular traps: insights from clinical cases and ex vivo study. Rheumatology 2026; 65(7) doi: 10.1093/rheumatology/keag323
174
Thaís Meira Menezes, Caio Assis, Alcides Jairon Lacerda Cintra, Roberto Carlos Silva dos Santos, Wilka Karla Martins do Vale, Regildo Max Gomes Martins, Ranilson de Souza Bezerra, Gustavo de Miranda Seabra, Chenglong Li, Jorge Luiz Neves. Binding Mechanism between Acetylcholinesterase and Drugs Pazopanib and Lapatinib: Biochemical and Biophysical Studies. ACS Chemical Neuroscience 2021; 12(24) doi: 10.1021/acschemneuro.1c00521
175
Zofia F. Bielecka, Agata Malinowska, Klaudia K. Brodaczewska, Aleksandra Klemba, Claudine Kieda, Paweł Krasowski, Elżbieta Grzesiuk, Jan Piwowarski, Anna M. Czarnecka, Cezary Szczylik. Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. Cell & Bioscience 2017; 7(1) doi: 10.1186/s13578-017-0197-8
176
Antonio Fernando Leis-Filho, Patrícia de Faria Lainetti, Priscila Emiko Kobayashi, Carlos Eduardo Fonseca-Alves, Renée Laufer-Amorim. Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro. Pharmaceutics 2021; 13(6) doi: 10.3390/pharmaceutics13060897
177
E. A. Shatokhina, A. G. Turkina, L. S. Kruglova. Dermatologic adverse events of Bcr-Abl tyrosine kinase inhibitors. Russian journal of hematology and transfusiology 2020; 65(2) doi: 10.35754/0234-5730-2020-65-2-154-173
178
Abdallah Alzoubi, Hassan Shirazi, Ahmad Alrawashdeh, Arwa M. AL-Dekah, Nadia Ibraheem, Khalid A. Kheirallah. The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature. Pharmaceutics 2024; 16(2) doi: 10.3390/pharmaceutics16020167
179
Priyanka Gupta, Keehn Strange, Rahul Telange, Ailan Guo, Heather Hatch, Amin Sobh, Jonathan Elie, Angela M. Carter, John Totenhagen, Chunfeng Tan, Yogesh A. Sonawane, Jiri Neuzil, Amarnath Natarajan, Ashley J. Ovens, Jonathan S. Oakhill, Thorsten Wiederhold, Karel Pacak, Hans K. Ghayee, Laurent Meijer, Sushanth Reddy, James A. Bibb. Genetic impairment of succinate metabolism disrupts bioenergetic sensing in adrenal neuroendocrine cancer. Cell Reports 2022; 40(7) doi: 10.1016/j.celrep.2022.111218
180
Jackson K. Nkoana, Garland K. More, Ahmed A. Elhenawy, Malose J. Mphahlele. Examining the 2-aryl-5-nitrobenzofuran-based hydrazones for anti-breast (MCF-7) cancer activity, potential to induce cell cycle arrest and inhibit receptor tyrosine kinases (VEGFR-2 & EGFR). European Journal of Medicinal Chemistry 2025; 298 doi: 10.1016/j.ejmech.2025.118018
181
Marwa A. Fouad, Alaa A. Osman, Noha M. Abdelhamid, Mai W. Rashad, Ashrakat Y. Nabawy, Ahmed M. El Kerdawy. Discovery of dual kinase inhibitors targeting VEGFR2 and FAK: structure-based pharmacophore modeling, virtual screening, and molecular docking studies. BMC Chemistry 2024; 18(1) doi: 10.1186/s13065-024-01130-5
182
Kiran Mahajan, Nupam P. Mahajan. ACK1 tyrosine kinase: Targeted inhibition to block cancer cell proliferation. Cancer Letters 2013; 338(2) doi: 10.1016/j.canlet.2013.04.004
183
Xinyang Liu, Xinyi Fan, Yihuan Wang, Lili Wang, Dehao Lu, Yuhui Wang, Xiangzheng Meng, Leli Fan, Wenjing Zhu, Xinlin Liu, Li Ye, Peng Sun. Trispecific antibodies in cancer therapy: Mechanisms, clinical progress and future directions. International Immunopharmacology 2026; 177 doi: 10.1016/j.intimp.2026.116503
184
Yael Aschner, Gregory P. Downey. The Importance of Tyrosine Phosphorylation Control of Cellular Signaling Pathways in Respiratory Disease: pY and pY Not. American Journal of Respiratory Cell and Molecular Biology 2018; 59(5) doi: 10.1165/rcmb.2018-0049TR
185
Refaah Mousa Al‐Jassas, Mohammad Shahidul Islam, Abdullah Mohammed Al‐Majid, Mohamed S. Nafie, Matti Haukka, A.F.M. Motiur Rahman, Abdul Majeed Abdullah Alayyaf, Assem Barakat. Synthesis and SARs study of novel spiro‐oxindoles as potent antiproliferative agents with CDK‐2 inhibitory activities. Archiv der Pharmazie 2023; 356(8) doi: 10.1002/ardp.202300185
186
Aleksandra Sochacka-Ćwikła, Marcin Mączyński, Andrzej Regiec. FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review. Cancers 2021; 14(1) doi: 10.3390/cancers14010087
187
Jose Luis Gonzalez-Llerena, Daniela Treviño-Almaguer, Jesus Alejandro Leal-Mendez, Gael Garcia-Valdez, Arely Guadalupe Balderas-Moreno, Michel Stéphane Heya, Isaias Balderas-Renteria, María del Rayo Camacho-Corona, Bryan Alejandro Espinosa-Rodriguez. The Cordyceps Genus as a Potential Source of Bioactive Compounds for Adjuvant Cancer Therapy: A Network Pharmacology Approach. Pharmaceuticals 2025; 18(5) doi: 10.3390/ph18050667
188
Burcu Cakar, Erdem Göker. Breast Disease. 2019;  doi: 10.1007/978-3-030-16792-9_35
189
Wagdy M. Eldehna, Ghada H Al-Ansary, Tarfah Al-Warhi, Maiy Y Jaballah, Mahmoud Elaasser, Mahmoud Rashed. Identification of novel ureido benzothiophenes as dual VEGFR-2/EGFR anticancer agents. Bioorganic Chemistry 2024; 143 doi: 10.1016/j.bioorg.2023.107037
190
Jackson K. Nkoana, Garland K. More, Ahmed A. Elhenawy, Malose J. Mphahlele. Development of the 5-Nitrosalicaldehyde Arylhydrazones as Anticancer (MCF-7 and HCT116) Agents Targeting Inhibition of VEGFR-2 and Cytokines (IL-6 and TNF-α). ACS Omega 2025;  doi: 10.1021/acsomega.5c07719
191
Godefridus J Peters, Richard J Honeywell. Drug transport and metabolism of novel anticancer drugs. Expert Opinion on Drug Metabolism & Toxicology 2015; 11(5) doi: 10.1517/17425255.2015.1041255
192
Diego Carvalho, Margot Paulino, Fabio Polticelli, Florencia Arredondo, Robert J. Williams, Juan A. Abin-Carriquiry. Structural evidence of quercetin multi-target bioactivity: A reverse virtual screening strategy. European Journal of Pharmaceutical Sciences 2017; 106 doi: 10.1016/j.ejps.2017.06.028
193
Hao-tian Zhang, Lu Wang, Jing Ai, Yi Chen, Chang-xi He, Yin-chun Ji, Min Huang, Jing-yu Yang, Ao Zhang, Jian Ding, Mei-yu Geng. SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-MET–Dependent Neoplastic Effects and Exerts Antitumor Activity. The Journal of Pharmacology and Experimental Therapeutics 2014; 350(1) doi: 10.1124/jpet.114.214817
194
Ting Guo, Shutao Ma. Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. ChemMedChem 2021; 16(4) doi: 10.1002/cmdc.202000658
195
GJ Peters. Precision medicine in cancer: beyond wishful thinking?. Expert Review of Precision Medicine and Drug Development 2016; 1(1) doi: 10.1080/23808993.2016.1140555
196
Daniel Dahis, Dana Meron Azagury, Fadi Obeid, Michelle Z. Dion, Alexander M. Cryer, Mariana Alonso Riquelme, Pere Dosta, Ariel William Abraham, Moshe Gavish, Natalie Artzi, Yosi Shamay, Haim Azhari. Focused Ultrasound Enhances Brain Delivery of Sorafenib Nanoparticles. Advanced NanoBiomed Research 2023; 3(2) doi: 10.1002/anbr.202200142
197
Rajesh Kumar, Monika Sharma, Sarita Sharma, Rajesh K. Singh. Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I. 2022;  doi: 10.2174/9789815040074122010006
198
Wagdy M. Eldehna, Raed M. Maklad, Hadia Almahli, Tarfah Al-Warhi, Eslam B. Elkaeed, Mohammed A. S. Abourehab, Hatem A. Abdel-Aziz, Ahmed M. El Kerdawy. Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights . Journal of Enzyme Inhibition and Medicinal Chemistry 2022; 37(1) doi: 10.1080/14756366.2022.2062337
199
Ru-zhen Chen, Rui Li, Bing-lin Cheng, Si-bei Lu, Wen Hu, Feng Lin, Xin Wen, Yue Chen, Ying-lei Wang, Mo-ting Zhang, Xiao-hong Hong, Xin-ran Tang. WNK1 promotes head and neck squamous cell carcinoma progression through activation of NF-κB signaling pathway. Discover Oncology 2025; 16(1) doi: 10.1007/s12672-025-03637-2
200
Ashley Jones, Samuele Bonomi, Keith E. Stockerl‐Goldstein, Randall J. Bateman. Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib. Annals of Clinical and Translational Neurology 2026; 13(4) doi: 10.1002/acn3.70296
201
Ranjana K. Kanchan, Jawed A. Siddiqui, Sidharth Mahapatra, Surinder K. Batra, Mohd W. Nasser. microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy. Molecular Cancer 2020; 19(1) doi: 10.1186/s12943-020-1140-x
202
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017;  doi: 10.1016/B978-0-12-809400-6.00006-8
203
Pooja Gupta, Tavneet Kaur Makkar, Lavisha Goel, Monika Pahuja. Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity. Immunologic Research 2022; 70(6) doi: 10.1007/s12026-022-09307-7
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.